Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05105100 · ClinicalTrials.gov registry record
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 25
- Enrollment target
NCT05105100: Completed study, sponsored by University of California, San Francisco.
NCT05105100 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05105100 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This is a non-therapeutic study assessing peripheral T cell determinants of response and resistance to immunotherapy in patients with advanced melanoma.The hypothesis is that systemic T cells traffic into the tumor microenvironment (TME) can predict response and resistance to immunotherapy. These systemic tumor directed T cells can be defined by tumor/blood small conditional RNA (scRNA) using T cell receptor (TCR) as a barcode and can help predict response to Programmed death-1 (PD-1) therapy.
Primary Outcome
The investigators will identify the genes predictive of response to anti-programmed death-1(PD-1) therapy by testing for significant associations across expression rates of each gene and response/resistance, within a hurdle-Gaussian mixed-effect framework that accounts for variance across patients and technical noise present in single-cell data. The overall number of genes predictive of response at baseline will be reported.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-10-29 |
| Est. Completion | 2025-09-15 |
What the finished NCT05105100 record still lists
NCT05105100 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT05105100 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05105100 about?
NCT05105100 is a clinical study titled "Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma". This is a non-therapeutic study assessing peripheral T cell determinants of response and resistance to immunotherapy in patients with advanced melanoma.The hypothesis is that systemic T cells traffic into the tumor microenvironment (TME) can predict response and resistance to immunotherapy. These sy...
What is the current status of trial NCT05105100?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2021-10-29. Estimated completion is 2025-09-15.
What interventions are being tested in trial NCT05105100?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT05105100?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI